Aim: To investigate the effects of the potassium-sparing diuretic amiloride on endothelial cell apoptosis during lipopolysaccharide (LPS)-accelerated atherosclerosis. Methods: Human umbilical vein endothelial cells (HUVECs) were exposed to LPS (100 ng/mL) in the presence of drugs tested. The activity of Na + /H + exchanger 1 (NHE1) and calpain, intracellular free Ca 2+ level ([Ca 2+ ] i ), as well as the expression of apoptosis-related proteins in the cells were measured. For in vivo study, ApoE-deficient (ApoE -/-) mice were fed high-fat diets with 0.5% (w/w) amiloride for 4 weeks and LPS (10 µg/mouse) infusion into caudal veins. Afterwards, atherosclerotic lesions, NHE1 activity and Bcl-2 expression in the aortic tissues were evaluated. Results: LPS treatment increased NHE1 activity and [Ca 2+ ] i in HUVECs in a time-dependent manner, which was associated with increased activity of the Ca 2+ -dependent protease calpain. Amiloride (1−10 µmol/L) significantly suppressed LPS-induced increases in NHE1 activity, [Ca 2+ ] i . and calpain activity. In the presence of the Ca 2+ chelator BAPTA (0.5 mmol/L), LPS-induced increase of calpain activity was also abolished. In LPS-treated HUVECs, the expression of Bcl-2 protein was significantly decreased without altering its mRNA level. In the presence of amiloride (10 µmol/L) or the calpain inhibitor ZLLal (50 µmol/L), the down-regulation of Bcl-2 protein by LPS was blocked. LPS treatment did not alter the expression of Bax and Bak proteins in HUVECs. In the presence of amiloride, BAPTA or ZLLal, LPS-induced HUVEC apoptosis was significantly attenuated. In ApoE -/-mice, administration of amiloride significantly suppressed LPS-accelerated atherosclerosis and LPS-induced increase of NHE1 activity, and reversed LPS-induced down-regulation of Bcl-2 expression. Conclusion: LPS stimulates NHE1 activity, increases [Ca 2+ ] i , and activates calpain, which leads to endothelial cell apoptosis related to decreased Bcl-2 expression. Amiloride inhibits NHE1 activity, thus attenuates LPS-accelerated atherosclerosis in mice.
Introduction
Atherosclerosis is a common cardiovascular disease characterized by the deposition of fatty substances on and fibrosis of the inner lining of the arteries. Amiloride is a potassiumsparing diuretic used in the management of hypertension and congestive heart failure. Amiloride was also tested as a treatment of cystic fibrosis and an inhibitor of Na + /H + exchanger 1 (NHE1) [1] . However, it has not been reported whether amiloride has a potentially beneficial effect as an anti-atherosclerotic treatment.
Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative bacteria and elicits inflammatory responses in immune and non-immune cells, including endothelial cells [2] . LPS can induce endothelial cell injury by activating calpain [3] and accelerate atherosclerosis in mice. During septic shock, endothelial cells are injured by LPS, which leads to vascular complications including thrombosis [4, 5] . Indeed, systemic organ failure induced by LPS is instigated by vascular endothelial damage, including cell death, perivascular accumulation of leukocytes, and vascular occlusion [6] . Vascular endothelial apoptosis is mediated by various mechanisms, such as free radicals, cytokines, cell interaction and death receptors, all of which can contribute to atherosclerosis.
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The induction of apoptosis by NHE1 activation has been extensively studied. NHE1 is ubiquitously expressed in the plasma membrane of eukaryotes and exchanges extracellular Na + for intracellular H + to regulate intracellular pH (pH i ) value and Na + i concentration [7] . The activation of NHE1 increases Na + i concentration, which leads to an overload of [Ca 2+ ] i through the Na + /Ca 2+ exchanger that contributes to cell dysfunction and damage in hepatocytes [8] . Increased intracellular Ca 2+ activates calpains, which are Ca 2+ -dependent proteases [9] that have been shown to regulate anti-apoptotic proteins including Bcl-2 [10] . Previous studies have shown that LPSinduced apoptosis is dependent on changes in Bcl-2 levels [11, 12] . Based on these results, we hypothesized that LPS-induced atherosclerosis is mediated by calpain-induced endothelial cell apoptosis. Our results provide new explanations of the underlying mechanisms of LPS-induced endothelial cell apoptosis and the anti-atherosclerosis effect of amiloride.
Materials and methods

Materials
Amiloride and ZLLal (benzyloxycarbonyl-leucyl-leucinal) were purchased from Biomol Research Laboratories, PA, USA. The calcium chelator, BAPTA, was purchased from Invitrogen Corporation. 2-Carboxyethyl-5(6)-carboxyfluorescein (BCECF) was purchased from Calbiochem (USA). Other chemicals were purchased from Sigma Chemical Co, USA. Anti-Bak, Bcl-2, Bax, β-actin, and secondary antibodies were purchased from Cell Signaling Technology, Inc(Danvers, MA, USA).
Mice
Male apolipoprotein E knockout (ApoE -/-) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). 6-to 8-week-old mice were used in the experiments. All of the mice were fed high-fat diets with or without 0.5% (w/w) amiloride for 4 weeks and LPS (10 ug/mouse) infusion into caudal veins. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by Jilin University.
Cell culture
HUVECs were purchased from ATCC and cultured according to the method described previously [13] . HUVECs were grown in EBM (Clonetics Inc, Walkersville, MD, USA) supplemented with 12.5 mg/mL ECGF, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1 mg/mL hydrocortisone. Cells were subcultured when 80%-90% confluent. Cells in passages 3-8 were used for all of the experiments.
Western blot
HUVECs were lysed in 1×cell-lysis buffer (Cell Signaling Technology, Inc, Danvers, MA, USA), and the protein content was determined by using a BCA protein assay reagent (Pierce, USA). Approximately 20-40 µg of protein was separated by 8%-10% SDS-PAGE and then transferred to nitrocellulose membrane. The membrane was incubated with a 1:1000 dilution of primary antibody overnight at 4 °C, followed by a 1:2000 dilution of horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. The protein bands were visualized by enhanced chemiluminescence (Amersham Biosciences). The band densities were measured by densitometry (model GS-700, Imaging Densitometer; Bio-Rad). The background was subtracted from the calculated area.
RT-PCR analysis for Bcl-2 mRNA Total RNA was isolated by a TRIzol (Life Technologies, USA) reagent according to the manufacturer's protocol [14] . The primer sequences used are as follows: Bcl-2 sense, 5'-GTGGATGACTGAGTACCTGAACC-3'; Bcl-2 antisense, 5'-AGCCAGGAGAAATCAAACAGAG-3'; GAPDH sense, 5'-TCATTTCCTGGTATGACAACG-3'; and GAPDH antisense, 5'-TTACTCCTTGGAGGCCATGT-3'. The PCR protocol for Bcl-2 is consisted of (1) 
Measurement of NHE1 activity in HUVECs
The NHE1 activity in HUVECs or aortic tissue in situ was assayed using a NH 4 Cl pulse method [15] . Briefly, cells were washed with HCO When 100 mmol/L of NaCl was added, the intracellular H + was pumped out via NHE1, and the pH i increased linearly. This initial rate of pH i recovery (dpH i /dt) reflects the NHE1 activity.
Determination of calpain activity
We used the fluorogenic peptide Suc-Leu-Leu-Val-Tyr-AMC to assay calpain activity as described previously with some modifications [16] . Briefly, cells were cultured in 24-well plates and washed with PBS, and 80 μmol/L of fluorogenic peptide was added. The fluorescence intensity was immediately recorded at 2-min intervals for 20 min at an excitation wavelength of 360 nm and emission wavelength of 460 nm with a Synergy HT Multi-Detection Microplate Reader (BIO-TEK Instruments Inc, Winooski, USA). We used the initial rate of peptidyl-AMC hydrolysis as the activity of the calpain enzyme.
Measurement of Ca
2+
i concentration The intracellular Ca 2+ i level was assayed using a Fluo-4 NW kit (Invitrogen), as described previously [17] . Shortly after treatment, the medium was aspirated, the cells were washed with HEPES buffer (pH 7.4), and 1 mL of HEPES buffer containing fluorescent dye was added to the cultured cells. After 30 min 
Apoptosis assay by TUNEL in HUVECs
HUVECs were washed with cold PBS and then fixed with 4% paraformaldehyde in PBS overnight. Cell apoptosis was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining (TMR red) using a kit (Roche Applied Science) and following the provided instruction manual [18] . The percentage of apoptosis was calculated from the number of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells divided by the total number of cells counted.
DNA fragmentation assay in HUVECs DNA from HUVECs was extracted with a Quick Apoptosis DNA Ladder Detection Kit (MBL, Nagoya, Japan). The samples were then loaded onto 1.5% agarose gel. After electrophoresis, the gel was subsequently stained with ethidium bromide and visualized under UV illumination [19] .
Atherosclerotic lesion analysis
The aortic tissue up to the ileal bifurcation was removed and fixed in 4% paraformaldehyde for 16 h. The adventitia was then thoroughly removed under a dissecting microscope. For each mouse, four consecutive sections were stained with Hematoxylin and Eosin (HE). The plaque images were captured using an Olympus microscope connected to a QImaging Retiga CCD camera. The aortic lesion size in each animal was obtained by averaging the lesion areas in the four sections. The lesion area, from the aortic arch to 5 mm distal to the left subclavian artery, was quantified using the Alpha Ease FC software (Version 4.0, Alpha Innotech, Miami, USA).
Immunohistochemistry
The aortic section was dissected, fixed in 4% paraformaldehyde for 16 h, and embedded in paraffin. Four micron-thick sections were deparaffinized, rehydrated, and microwaved in citrate buffer for antigen retrieval. The sections were successively incubated in endogenous peroxidase and alkaline phosphatase block buffer (DAKO), protein block buffer, and primary antibodies, with the antibody incubation being performed overnight at 4 °C. After rinsing in wash buffer, the sections were incubated with labeled polymer-horseradish peroxidase anti-mouse or anti-rabbit antibodies and DAB chromogen. Alternatively, they were incubated with polymeralkaline phosphatase anti-mouse or anti-rabbit antibody and Permanent Red chromogen (EnVision™ G|2 Doublestain System, DAKO). After the final washes, the sections were counterstained with hematoxylin.
Statistical analysis
The statistical analyses were performed using the SPSS10.0 software. The data are expressed as the mean±SEM. The statistical significance of differences was evaluated by using oneway ANOVA followed by Student's t-test. P<0.05 was considered statistically significant.
Results
LPS induces increased activation of NHE1 activity and intracellular calcium
Earlier studies have shown that LPS induces endothelial cell apoptosis and endothelial dysfunction, which contributes to cardiovascular disease [20] . However, the mechanisms leading to LPS-induced endothelial cell apoptosis are not welldefined. We first determined whether LPS could activate NHE1 in HUVECs. As shown in Figure 1A , LPS stimulation of HUVECs induced an increase in NHE1 activity beginning at 4 h and peaking at 16 h post-stimulation. NHE1 activity remained elevated at 48 h.
The activation of NHE1 increases Na + i , which leads to intracellular Ca 2+ overload via the Na + /Ca 2+ exchanger and plays a crucial role in many diseases, including ischemia [21] and atherosclerosis [22] . We further investigated whether the activation of NHE1 by LPS resulted in increased intracellular calcium levels. As shown in Figure 1C , LPS increased intracellular calcium levels in HUVECs in a time-dependent manner. Thus, LPS induces increases in NHE1 activity that is associated with significant increases in intracellular calcium in HUVECs.
Amiloride prevents the induction of NHE1 and increases in intracellular calcium
To confirm the specific activation of NHE1 by LPS, we treated HUVECs with amiloride, a well-known NHE1 inhibitor. As shown in Figure 1B , amiloride prevented LPS-induced increases in NHE1 activity in a dose-dependent manner. Additionally, the LPS-induced increase in intracellular calcium was reversed by amiloride treatment ( Figure 1D ). These data confirm that the LPS-induced increase in intracellular calcium depends on NHE1.
LPS-enhanced calpain activity is both NHE1 and calcium dependent Calpains are a family of Ca 2+ -dependent cysteine proteases found in mammals and many lower organisms [17, 23] . In the presence of elevated Ca 2+ i concentration, calpains are activated and regulate cellular function by degrading many intracellular proteins [24, 25] . Given the LPS-induced increases in intracellular calcium, we determined whether LPS also induced calpain activity in HUVECs. As seen in Figure 1E and 1F, LPS stimulation of HUVECs induced significant increases in calpain activity. Inhibition of NHE1 by amiloride or chelation of intracellular Ca 2+ by BAPTA effectively abolished LPSinduced increases in calpain activity. Taken together, these data indicate that LPS induces activation of NHE1, resulting in the elevation of Ca 2+ i and causing the activation of calpains.
Inhibition of NHE1 by amiloride abolishes LPS-induced downregulation of Bcl-2 protein
The anti-apoptotic members of the Bcl family (Bcl-xL, Bcl-2, etc) play important roles in regulating cell death [26, 27] . We determined whether LPS-increased calpain activity induced www.nature.com/aps Cui GM et al Acta Pharmacologica Sinica npg the degradation of Bcl-2. As shown in Figure 2A , HUVECs treated with LPS significantly reduced Bcl-2 levels compared to control cells. The inhibition of NHE1 by amiloride treatment abolished the LPS-induced decrease in Bcl-2 protein levels. Amiloride treatment with LPS prevented the reduction in Bcl-2 protein, suggesting that NHE1 activity is required to decrease Bcl-2 levels. The reductions in Bcl-2 protein levels could be due to a LPSinduced repression of Bcl-2 gene transcription. To exclude this possibility, we determined the mRNA levels of Bcl-2 during HUVEC treatment with LPS. As indicated in Figure 2B , LPS stimulation failed to alter Bcl-2 mRNA levels. Amiloride had no effect on the Bcl-2 mRNA level. These data suggest that LPS decreases Bcl-2 protein levels, most probably via protein degradation rather than by decreasing the transcription activity of Bcl-2.
LPS-induced reduction in Bcl-2 is inhibited by the calpain inhibitor, ZLLal
To determine whether LPS-induced Bcl-2 degradation is mediated by calpain, we treated HUVECs with LPS in the absence or presence of the calpain inhibitor, ZLLal. As shown in Figure 2C , the inhibition of calpain by ZLLal prevented LPSinduced decreases in Bcl-2 protein levels. These data indicate that LPS-induced reductions in Bcl-2 are calpain-dependent.
It is reported that other apoptosis-related genes, such as the pro-apoptotic genes Bax and Bak, are involved in cell apoptosis [28] . To investigate whether both Bax and Bak also play roles in LPS-induced apoptosis of HUVECs, we determined the levels of Bax and Bak in the presence or absence of LPS. As shown in Figure 2D , Bax and Bak levels remained stable in the presence or LPS or ZLLal. Thus, Bcl-2 is uniquely degraded in a calpain-dependent manner in LPS-treated HUVECs.
LPS-induced endothelial cell apoptosis requires NHE1, calcium mobilization, and calpain activation The apoptosis of endothelial cells is very important in the process of atherosclerosis. Because LPS induced the degradation of the anti-apoptotic protein Bcl-2, we determined the apoptosis rates in LPS-treated HUVECs. As shown in Figure 3A and 3B, LPS induced significant increases in HUVEC apoptosis compared with PBS-treated controls, as indicated by positive TUNEL staining. The LPS-induced apoptosis was further confirmed by DNA fragmentation ( Figure 3D ). The inhibition of calpain activation by amiloride, BAPTA, or ZLLal significantly inhibited LPS-induced apoptosis of HUVECs while having no effect on control cells (Figures 3A and 3B) . Amiloride, BAPTA, and ZLLal also effectively prevented LPS-induced DNA fragmentation ( Figure 3C ). These data indicate that LPS-induced HUVEC apoptosis depends on NHE1 activation, increases in intracellular calcium, and calpain activation. Our data suggest that amiloride may have significant effects on LPS-induced atherosclerosis by inhibiting NHE1 activation and endothelial apoptosis. To test this hypothesis, we investigated whether amiloride could prevent LPS-induced atherosclerosis in vivo. ApoE -/-mice on a high-fat diet were treated with or without LPS and with or without 0.5% amiloride (w/w) for 4 weeks. Compared with control ApoE -/-mice on a high-fat diet, LPS remarkably accelerated atherosclerotic lesion formation in the aorta ( Figure 4A ). Amiloride suppressed the accelerated atherosclerotic lesions in LPS-treated mice. To assess endothelial apoptosis, we performed immunohistochemistry for Bcl-2 in representative aortic lesions. As shown in Figure  4B , LPS decreased the expression of Bcl-2, whereas amiloride treatment in the presence of LPS led to significant increases in the expression of Bcl-2.
To confirm whether LPS activates NHE1 in vivo, we determined the activity of NHE1 in extracts of mouse aorta tissue. As shown in Figure 4C , LPS significantly increased the activity of NHE1 within the aorta. The administration of amiloride attenuated this LPS-induced increase in NHE1 activity. Surprisingly, NHE1 activity in control mice was unchanged with amiloride treatment. Taken together, our data indicate that LPS-accelerated atherosclerosis may occur via activation of NHE1 leading to changes in Ca 2+ i , activation of calpain, and degradation of Bcl-2, thus driving endothelial apoptosis and lesion formation. Inhibiting the NHE1 pathway by amiloride effectively suppressed these downstream effects and prevented LPS-induced atherosclerosis.
Discussion
The current study demonstrates that amiloride attenuates LPS-accelerated atherosclerosis by inhibiting NHE1-dependent calpain-mediated Bcl-2 degradation in endothelial cells. The inhibition of NHE1 by amiloride reversed LPS-induced increases in intracellular calcium and calpain activity. In addition, the inhibition of either NHE1 by amiloride or calpain by ZLLal blocked Bcl-2 degradation caused by LPS. These results strongly suggest that NHE1 is required for LPS-induced Endothelial cell injury is common in the pathogenesis of several diseases, including atherosclerosis [29] , hypertension [30] , and congestive heart failure [31] . During bacterial sepsis, endothelial cell death is the final step of a process that begins when quiescent endothelial cells are induced to express pro-coagulant, pro-adhesive, and vasoconstrictive factors. Results from this study demonstrate that LPS induces apoptosis in HUVECs in a NHE1-and calpain-dependent manner. These findings agree with those obtained in other species, both in vitro and in vivo [32, 33] . Our data clearly indicate that LPS-induced apoptosis is mediated by NHE1 via the calcium/calpain pathway. Calpains are a family of calcium-dependent proteases that act independently of the proteasome pathway and cleave a number of cellular substrates, including kinases, phosphatases, transcription factors, and cytoskeletal proteins [34] . In this study, we found that LPS increased the intracellular calcium and calpain activity in vascular endothelial cells. The chelation of intracellular free-calcium by BAPTA effectively prevented calpain activation and induction of apoptosis by LPS.
Our data also indicate that LPS-induced NHE1 activation is effectively inhibited in vitro and in vivo by amiloride. One potential mechanism of the LPS-induced increase of NHE1 activity may involve either a phosphorylation-dependent increase in the activity of existing exchangers or the activation of dormant membrane-associated exchangers. In fact, Sardet et al [35] , have demonstrated that NHE1 is rapidly phosphorylated in response to various mitogens and concluded that this phosphorylation of NHE1 is temporally correlated with its activation. Additional studies are needed to determine the precise mechanism of NHE1-activation by LPS and how amiloride alters this activation.
The anti-apoptotic Bcl-2 protein is localized to outer mitochondrial membrane and functions to prevent cytochrome c release from mitochondria [36] . Here, we found that LPS induced reductions in Bcl-2 protein levels in HUVECs that could be prevented by treatment with amiloride or calpain inhibitor ZLLal; the mRNA levels of Bcl-2 were not affected. All of the results indicate that calpain participates in the LPSinduced degradation of Bcl-2; however, it remains unclear www.chinaphar.com Cui GM et al Acta Pharmacologica Sinica npg which calpain isoform is involved and whether Bcl-2 is the direct substrate of calpain in LPS-treated HUVECs.
In conclusion, the inhibition of NHE1 by amiloride completely blocked LPS-induced atherosclerosis in mice and is mediated by calcium and calpain-dependent Bcl-2 degradation in HUVECs ( Figure 4D ). The inhibition of NHE1 could be a promising novel approach to halt or even reverse atherosclerosis in patients. 
